An overview of complications associated with deferoxamine therapy in thalassemia
Thalassemic syndromes are the most common genetic diseases in the world that are related to blood transfusion and iron overload in the body. In ß-thalassemia major multiple blood transfusions due to ineffective erythropoiesis lead to iron excess in the body. Iron chelating agent deferoxamine is used...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Society of Diabetic Nephropathy Prevention
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ae3243204daa484abb5acd62d0025edf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ae3243204daa484abb5acd62d0025edf |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ae3243204daa484abb5acd62d0025edf2021-11-17T08:13:57ZAn overview of complications associated with deferoxamine therapy in thalassemia2345-420210.34172/npj.2021.05https://doaj.org/article/ae3243204daa484abb5acd62d0025edf2021-01-01T00:00:00Zhttps://jnephropharmacology.com/PDF/npj-10346https://doaj.org/toc/2345-4202Thalassemic syndromes are the most common genetic diseases in the world that are related to blood transfusion and iron overload in the body. In ß-thalassemia major multiple blood transfusions due to ineffective erythropoiesis lead to iron excess in the body. Iron chelating agent deferoxamine is used to treat chronic iron overload in patients with β-thalassemia in an attempt to reduce morbidity and mortality related to deposition of excess iron in body tissue. However, a very short half-time, the need of repetitive injections and non-specialized distribution in tissues can lead to side effects, such as ophthalmic and renal complications, neurological, skeletal changes and hearing loss, headaches, and infection too. Patients should be monitored periodically for complications. The risk of toxic effects in doses of more than 50 mg/kg/d is higher. Keeping deferoxamine therapeutic index can avoid drug overdose and side effects.Bijan KeikhaeiNeda Farmani-AnoosheMohammad BahadoramMohammad-Reza Mahmoudian-SaniKosar AlikhaniAmmar HelalinasabSociety of Diabetic Nephropathy Prevention articledeferoxaminethalassemiachelatorsTherapeutics. PharmacologyRM1-950Diseases of the genitourinary system. UrologyRC870-923ENJournal of Nephropharmacology, Vol 10, Iss 1, Pp e05-e05 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
deferoxamine thalassemia chelators Therapeutics. Pharmacology RM1-950 Diseases of the genitourinary system. Urology RC870-923 |
| spellingShingle |
deferoxamine thalassemia chelators Therapeutics. Pharmacology RM1-950 Diseases of the genitourinary system. Urology RC870-923 Bijan Keikhaei Neda Farmani-Anooshe Mohammad Bahadoram Mohammad-Reza Mahmoudian-Sani Kosar Alikhani Ammar Helalinasab An overview of complications associated with deferoxamine therapy in thalassemia |
| description |
Thalassemic syndromes are the most common genetic diseases in the world that are related to blood transfusion and iron overload in the body. In ß-thalassemia major multiple blood transfusions due to ineffective erythropoiesis lead to iron excess in the body. Iron chelating agent deferoxamine is used to treat chronic iron overload in patients with β-thalassemia in an attempt to reduce morbidity and mortality related to deposition of excess iron in body tissue. However, a very short half-time, the need of repetitive injections and non-specialized distribution in tissues can lead to side effects, such as ophthalmic and renal complications, neurological, skeletal changes and hearing loss, headaches, and infection too. Patients should be monitored periodically for complications. The risk of toxic effects in doses of more than 50 mg/kg/d is higher. Keeping deferoxamine therapeutic index can avoid drug overdose and side effects. |
| format |
article |
| author |
Bijan Keikhaei Neda Farmani-Anooshe Mohammad Bahadoram Mohammad-Reza Mahmoudian-Sani Kosar Alikhani Ammar Helalinasab |
| author_facet |
Bijan Keikhaei Neda Farmani-Anooshe Mohammad Bahadoram Mohammad-Reza Mahmoudian-Sani Kosar Alikhani Ammar Helalinasab |
| author_sort |
Bijan Keikhaei |
| title |
An overview of complications associated with deferoxamine therapy in thalassemia |
| title_short |
An overview of complications associated with deferoxamine therapy in thalassemia |
| title_full |
An overview of complications associated with deferoxamine therapy in thalassemia |
| title_fullStr |
An overview of complications associated with deferoxamine therapy in thalassemia |
| title_full_unstemmed |
An overview of complications associated with deferoxamine therapy in thalassemia |
| title_sort |
overview of complications associated with deferoxamine therapy in thalassemia |
| publisher |
Society of Diabetic Nephropathy Prevention |
| publishDate |
2021 |
| url |
https://doaj.org/article/ae3243204daa484abb5acd62d0025edf |
| work_keys_str_mv |
AT bijankeikhaei anoverviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT nedafarmanianooshe anoverviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT mohammadbahadoram anoverviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT mohammadrezamahmoudiansani anoverviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT kosaralikhani anoverviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT ammarhelalinasab anoverviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT bijankeikhaei overviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT nedafarmanianooshe overviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT mohammadbahadoram overviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT mohammadrezamahmoudiansani overviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT kosaralikhani overviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia AT ammarhelalinasab overviewofcomplicationsassociatedwithdeferoxaminetherapyinthalassemia |
| _version_ |
1718425819297087488 |